Funding
Series A · Biotech

Breye Therapeutics raises €67.5m Series A for oral retinal therapies

Mission BioCapital and Novo Holdings co-led the financing to advance danegaptide and Breye’s retinal disease pipeline.

By RoundOS Funding desk

Breye Therapeutics announced a €67.5 million Series A on 29 September 2026, co-led by Mission BioCapital and Novo Holdings. Sound Bioventures, the Ljungström family office, Innovestor Life Science, EIFO, Catalyze Capital, Modi Ventures and Pappas Capital also participated.

The Danish company will use the funds to take danegaptide into a randomized Phase 2 study in non-proliferative diabetic retinopathy, planned for 2027. The financing also supports its broader pipeline of oral treatments for retinal diseases.

Use of funds

Advance danegaptide to randomized Phase 2

Develop retinal disease pipeline

Funding history

Series A · This round€67.5M
Seed€4M

Sources

  1. Breye Therapeutics funding announcementbreye.com · Sep 29, 2026

Similar rounds

All Biotech rounds →
Microbiotica

Microbiotica develops oral medicines made from selected live bacteria for inflammatory diseases and cancer treatment.

£36MSeries C first close · Oct 16, 2026
Estuary Biotherapeutics

Estuary Biotherapeutics develops locally delivered gene therapies for patients with inherited polycystic kidney disease.

$93MSeries A · Oct 16, 2026
AdipoSeeds

AdipoSeeds develops platelet-based regenerative medicine and platelet-processing technology.

UndisclosedStrategic investment · Oct 16, 2026
OMass Therapeutics

OMass Therapeutics develops small-molecule medicines for endocrine and immune diseases using a platform that measures drug targets in their biological surroundings.

$310MSeries C · Oct 15, 2026

Related